Neuropace, Inc. NPCE Proceeds from exercises of stock options and other stock issuances
Proceeds from exercises of stock options and other stock issuances at other companies
Other financials
Where this comes from
Reported directly by Neuropace, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.
The official record: Neuropace, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neuropace, Inc.'s proceeds from exercises of stock options and other stock issuances.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neuropace, Inc.'s proceeds from exercises of stock options and other stock issuances?
- Neuropace, Inc. (NPCE) reported proceeds from exercises of stock options and other stock issuances of $10K in Q1 2026.
- How has Neuropace, Inc.'s proceeds from exercises of stock options and other stock issuances changed year-over-year?
- Neuropace, Inc.'s proceeds from exercises of stock options and other stock issuances decreased by 97.4% year-over-year, from $385K to $10K.
- What is the long-term trend for Neuropace, Inc.'s proceeds from exercises of stock options and other stock issuances?
- Over 3 years (2022 to 2025), Neuropace, Inc.'s proceeds from exercises of stock options and other stock issuances has grown at a 27.9% compound annual growth rate (CAGR), from $896K to $1.88M.